Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - ELITE PHARMACEUTICALS INC /NV/ | v210059_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D)
OF THE
SECURITIES EXCHANGE ACT OF 1934
|
January 31, 2011
|
||
| Date of Report (Date of earliest event reported) | ||
|
ELITE PHARMACEUTICALS,
INC.
|
||
| (Exact name of registrant as specified in its charter) | ||
|
Delaware
|
001-15697
|
22-3542636
|
||||
|
(State or other
jurisdiction
|
(Commission
|
(IRS
Employer
|
||||
| of incorporation) |
File
Number)
|
Identification
No.)
|
||||
|
165 Ludlow Avenue, Northvale, New
Jersey 07647
|
||
| (Address of principal executive offices) | ||
|
(201)
750-2646
|
||
| (Registrant’s telephone number, including area code) | ||
|
(Former name or former address, if
changed since last report.)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
¨ Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01 Other Events.
On
February 4, 2011, the Company issued a press release announcing the approval of
an Abbreviated New Drug Application (ANDA) from the United States Food and Drug
Administration for 37.5 mg phentermine
HCI tablets. On September 16, 2010, the Company had
previously announced the acquisition of the ANDA for this generic product from
Epic Pharma LLC (“Epic”). The ANDA approval was granted under Epic
Pharma’s name and transfer of the ANDA into Elite’s name will begin
immediately.
A copy of
the press release, dated February 4, 2011, is attached as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated by reference herein.
Item
9.01 Financial Statements and Exhibits
a) Not
applicable.
b) Not
applicable.
c) Not
applicable.
d)
Exhibits
| Exhibit No. | Exhibit | |
|
99.1
|
Press Release dated February
4,
2011
|
SIGNATURE
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
Dated: February 4,
2011
|
ELITE PHARMACEUTICALS,
INC.
|
|||
|
By:
|
/s/ Chris
Dick
|
||
|
Name:
|
Chris
Dick
|
||
|
Title:
|
President & Chief Operating
Officer
|
||